17-DMAG (17-dimethylaminoethylamino-17-demethoxygeldanamycin) is a water-soluble, bioavailable analog of geldanamycin and 17-AAG, designed to overcome the solubility and toxicity limitations of its predecessors. As a high-affinity HSP90 inhibitor, 17-DMAG disrupts the stability of client proteins involved in neurodegenerative disease pathways. Preclinical studies highlight its ability to induce autophagy and promote the clearance of alpha-synuclein aggregates, a hallmark of Parkinson's disease and related disorders. Its favorable pharmacokinetic profile, including efficient tissue distribution and reduced metabolic degradation, makes 17-DMAG a compelling candidate for CNS-targeted therapies. By enhancing proteostasis and mitigating protein aggregation, 17-DMAG represents a promising tool for modulating neurodegenerative processes at the molecular chaperone level.
